Canagliflozin reduces epicardial fat in patients with type 2 diabetes mellitus
Abstract Background It is unknown whether canagliflozin, a selective sodium glucose co-transporter 2 inhibitor, reduces epicardial adipose tissue (EAT) thickness, which is associated with insulin resistance and is a risk factor for coronary artery disease. Methods and results We administered 100 mg...
| Main Authors: | , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2017-10-01
|
| Series: | Diabetology & Metabolic Syndrome |
| Subjects: | |
| Online Access: | http://link.springer.com/article/10.1186/s13098-017-0275-4 |
| _version_ | 1818326807711055872 |
|---|---|
| author | Shusuke Yagi Yukina Hirata Takayuki Ise Kenya Kusunose Hirotsugu Yamada Daiju Fukuda Hotimah Masdan Salim Gulinu Maimaituxun Susumu Nishio Yuriko Takagawa Saori Hama Tomomi Matsuura Koji Yamaguchi Takeshi Tobiume Takeshi Soeki Tetsuzo Wakatsuki Ken-ichi Aihara Masashi Akaike Michio Shimabukuro Masataka Sata |
| author_facet | Shusuke Yagi Yukina Hirata Takayuki Ise Kenya Kusunose Hirotsugu Yamada Daiju Fukuda Hotimah Masdan Salim Gulinu Maimaituxun Susumu Nishio Yuriko Takagawa Saori Hama Tomomi Matsuura Koji Yamaguchi Takeshi Tobiume Takeshi Soeki Tetsuzo Wakatsuki Ken-ichi Aihara Masashi Akaike Michio Shimabukuro Masataka Sata |
| author_sort | Shusuke Yagi |
| collection | DOAJ |
| description | Abstract Background It is unknown whether canagliflozin, a selective sodium glucose co-transporter 2 inhibitor, reduces epicardial adipose tissue (EAT) thickness, which is associated with insulin resistance and is a risk factor for coronary artery disease. Methods and results We administered 100 mg of canagliflozin for 6 months to 13 patients with type 2 diabetes mellitus. We evaluated glycemic control, visceral adipose tissue (VAT) area and subcutaneous adipose tissue (SAT) area, and skeletal muscle mass by using impedance methods, and EAT thickness by using echocardiography. Canagliflozin treatment for 6 months decreased hemoglobin A1c level from 7.1 ± 0.5% to 6.7 ± 0.6% (P < 0.05) and decreased EAT thickness from 9.3 ± 2.5 to 7.3 ± 2.0 mm (P < 0.001), along with a trend of decreasing VAT and SAT area. No association was found between any of these changes. Conclusion Canagliflozin reduced EAT thickness in patients with type 2 diabetes mellitus independent of its effect on lowering blood glucose, suggesting that canagliflozin may have an effect in preventing cardiovascular events in these patients (UMIN000021327). |
| first_indexed | 2024-12-13T12:06:15Z |
| format | Article |
| id | doaj.art-8e5336d81f7b48f3b467a8270bef0d68 |
| institution | Directory Open Access Journal |
| issn | 1758-5996 |
| language | English |
| last_indexed | 2024-12-13T12:06:15Z |
| publishDate | 2017-10-01 |
| publisher | BMC |
| record_format | Article |
| series | Diabetology & Metabolic Syndrome |
| spelling | doaj.art-8e5336d81f7b48f3b467a8270bef0d682022-12-21T23:46:57ZengBMCDiabetology & Metabolic Syndrome1758-59962017-10-01911710.1186/s13098-017-0275-4Canagliflozin reduces epicardial fat in patients with type 2 diabetes mellitusShusuke Yagi0Yukina Hirata1Takayuki Ise2Kenya Kusunose3Hirotsugu Yamada4Daiju Fukuda5Hotimah Masdan Salim6Gulinu Maimaituxun7Susumu Nishio8Yuriko Takagawa9Saori Hama10Tomomi Matsuura11Koji Yamaguchi12Takeshi Tobiume13Takeshi Soeki14Tetsuzo Wakatsuki15Ken-ichi Aihara16Masashi Akaike17Michio Shimabukuro18Masataka Sata19Department of Cardiovascular Medicine, Tokushima University Graduate School of Biomedical SciencesUltrasound Examination Center, Tokushima University HospitalDepartment of Cardiovascular Medicine, Tokushima University Graduate School of Biomedical SciencesDepartment of Cardiovascular Medicine, Tokushima University Graduate School of Biomedical SciencesDepartment of Cardiovascular Medicine, Tokushima University Graduate School of Biomedical SciencesDepartment of Cardiovascular Medicine, Tokushima University Graduate School of Biomedical SciencesDepartment of Cardiovascular Medicine, Tokushima University Graduate School of Biomedical SciencesDepartment of Cardiovascular Medicine, Tokushima University Graduate School of Biomedical SciencesUltrasound Examination Center, Tokushima University HospitalDepartment of Cardiovascular Medicine, Tokushima University Graduate School of Biomedical SciencesDepartment of Cardiovascular Medicine, Tokushima University Graduate School of Biomedical SciencesDepartment of Cardiovascular Medicine, Tokushima University Graduate School of Biomedical SciencesDepartment of Cardiovascular Medicine, Tokushima University Graduate School of Biomedical SciencesDepartment of Cardiovascular Medicine, Tokushima University Graduate School of Biomedical SciencesDepartment of Cardiovascular Medicine, Tokushima University Graduate School of Biomedical SciencesDepartment of Cardiovascular Medicine, Tokushima University Graduate School of Biomedical SciencesDepartment of Community Medicine for Diabetes and Metabolic Disorders, Tokushima University Graduate School of Biomedical SciencesDepartment of Medical Education, Tokushima University Graduate School of Biomedical SciencesDepartment of Cardio-Diabetes Medicine, Tokushima University Graduate School of Biomedical SciencesDepartment of Cardiovascular Medicine, Tokushima University Graduate School of Biomedical SciencesAbstract Background It is unknown whether canagliflozin, a selective sodium glucose co-transporter 2 inhibitor, reduces epicardial adipose tissue (EAT) thickness, which is associated with insulin resistance and is a risk factor for coronary artery disease. Methods and results We administered 100 mg of canagliflozin for 6 months to 13 patients with type 2 diabetes mellitus. We evaluated glycemic control, visceral adipose tissue (VAT) area and subcutaneous adipose tissue (SAT) area, and skeletal muscle mass by using impedance methods, and EAT thickness by using echocardiography. Canagliflozin treatment for 6 months decreased hemoglobin A1c level from 7.1 ± 0.5% to 6.7 ± 0.6% (P < 0.05) and decreased EAT thickness from 9.3 ± 2.5 to 7.3 ± 2.0 mm (P < 0.001), along with a trend of decreasing VAT and SAT area. No association was found between any of these changes. Conclusion Canagliflozin reduced EAT thickness in patients with type 2 diabetes mellitus independent of its effect on lowering blood glucose, suggesting that canagliflozin may have an effect in preventing cardiovascular events in these patients (UMIN000021327).http://link.springer.com/article/10.1186/s13098-017-0275-4Epicardial adipose tissueSGLT2 inhibitorsEchocardiography |
| spellingShingle | Shusuke Yagi Yukina Hirata Takayuki Ise Kenya Kusunose Hirotsugu Yamada Daiju Fukuda Hotimah Masdan Salim Gulinu Maimaituxun Susumu Nishio Yuriko Takagawa Saori Hama Tomomi Matsuura Koji Yamaguchi Takeshi Tobiume Takeshi Soeki Tetsuzo Wakatsuki Ken-ichi Aihara Masashi Akaike Michio Shimabukuro Masataka Sata Canagliflozin reduces epicardial fat in patients with type 2 diabetes mellitus Diabetology & Metabolic Syndrome Epicardial adipose tissue SGLT2 inhibitors Echocardiography |
| title | Canagliflozin reduces epicardial fat in patients with type 2 diabetes mellitus |
| title_full | Canagliflozin reduces epicardial fat in patients with type 2 diabetes mellitus |
| title_fullStr | Canagliflozin reduces epicardial fat in patients with type 2 diabetes mellitus |
| title_full_unstemmed | Canagliflozin reduces epicardial fat in patients with type 2 diabetes mellitus |
| title_short | Canagliflozin reduces epicardial fat in patients with type 2 diabetes mellitus |
| title_sort | canagliflozin reduces epicardial fat in patients with type 2 diabetes mellitus |
| topic | Epicardial adipose tissue SGLT2 inhibitors Echocardiography |
| url | http://link.springer.com/article/10.1186/s13098-017-0275-4 |
| work_keys_str_mv | AT shusukeyagi canagliflozinreducesepicardialfatinpatientswithtype2diabetesmellitus AT yukinahirata canagliflozinreducesepicardialfatinpatientswithtype2diabetesmellitus AT takayukiise canagliflozinreducesepicardialfatinpatientswithtype2diabetesmellitus AT kenyakusunose canagliflozinreducesepicardialfatinpatientswithtype2diabetesmellitus AT hirotsuguyamada canagliflozinreducesepicardialfatinpatientswithtype2diabetesmellitus AT daijufukuda canagliflozinreducesepicardialfatinpatientswithtype2diabetesmellitus AT hotimahmasdansalim canagliflozinreducesepicardialfatinpatientswithtype2diabetesmellitus AT gulinumaimaituxun canagliflozinreducesepicardialfatinpatientswithtype2diabetesmellitus AT susumunishio canagliflozinreducesepicardialfatinpatientswithtype2diabetesmellitus AT yurikotakagawa canagliflozinreducesepicardialfatinpatientswithtype2diabetesmellitus AT saorihama canagliflozinreducesepicardialfatinpatientswithtype2diabetesmellitus AT tomomimatsuura canagliflozinreducesepicardialfatinpatientswithtype2diabetesmellitus AT kojiyamaguchi canagliflozinreducesepicardialfatinpatientswithtype2diabetesmellitus AT takeshitobiume canagliflozinreducesepicardialfatinpatientswithtype2diabetesmellitus AT takeshisoeki canagliflozinreducesepicardialfatinpatientswithtype2diabetesmellitus AT tetsuzowakatsuki canagliflozinreducesepicardialfatinpatientswithtype2diabetesmellitus AT kenichiaihara canagliflozinreducesepicardialfatinpatientswithtype2diabetesmellitus AT masashiakaike canagliflozinreducesepicardialfatinpatientswithtype2diabetesmellitus AT michioshimabukuro canagliflozinreducesepicardialfatinpatientswithtype2diabetesmellitus AT masatakasata canagliflozinreducesepicardialfatinpatientswithtype2diabetesmellitus |